Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Jad Othman, Nicola Potter, Katya Mokretar, et al.
Leukemia (2023) Vol. 37, Iss. 10, pp. 2066-2072
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood (2024) Vol. 144, Iss. 7, pp. 714-728
Closed Access | Times Cited: 24
Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments
Mikhail Roshal, Qi Gao
American Journal of Clinical Pathology (2025)
Closed Access | Times Cited: 1
Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Emmanuel Gyan, Mark D. Minden, Kohmei Kubo, et al.
Cancer (2025) Vol. 131, Iss. 4
Open Access | Times Cited: 1
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML
Brunangelo Falini, Richard Dillon
Blood Cancer Discovery (2023) Vol. 5, Iss. 1, pp. 8-20
Open Access | Times Cited: 17
Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm
Hengzhou Zhu, C. C. Zhang, Lei Huang, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-12
Closed Access
Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience
Yusuke Uchibori, Shuhei Kurosawa, Yuho Najima, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Margery Gang, Megan Othus, Roland B. Walter
Cells (2025) Vol. 14, Iss. 4, pp. 290-290
Open Access
Determination of FLT3 mutations and minimal residual deasease monitoring in FLT3-positive acute myeloid leukemia
Yulia Sidorova, Nataliya Severina, Bella Biderman, et al.
Russian journal of hematology and transfusiology (2025) Vol. 70, Iss. 1, pp. 8-26
Open Access
Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
Ing Soo Tiong, Sun Loo
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4790-4790
Open Access | Times Cited: 12
NPM1 Measurable Residual Disease: A Narrative Review
Yadav Chitresh, Shrinidhi Nathany, Krishna Karthik, et al.
Indian Journal of Hematology and Blood Transfusion (2025)
Closed Access
Allogeneic stem cell transplantation for MDS—clinical issues, choosing preparative regimens and outcome
Lara Bischof, Lara Bischof, Uwe Platzbecker, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-14
Open Access
Ultrasensitive Detection of FLT3-ITD Mutations via Primer Competition Enhanced Mutant Accumulation
Ling Dai, Mengjun Deng, Kena Chen, et al.
Analytical Chemistry (2025)
Closed Access
Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts
Mathias Chéa, Lucie Rigolot, Alban Canali, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2150-2150
Open Access | Times Cited: 3
SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia
Aditya Tedjaseputra, Nigel H. Russell, Richard Dillon
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 11, pp. 737-751
Open Access | Times Cited: 3
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study
Corentin Orvain, Sarah Bertoli, Pierre Péterlin, et al.
Leukemia (2024) Vol. 38, Iss. 9, pp. 1949-1957
Open Access | Times Cited: 3
Perspective on measurable residual disease testing in acute myeloid leukemia
Roland B. Walter
Leukemia (2023) Vol. 38, Iss. 1, pp. 10-13
Closed Access | Times Cited: 8
Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions
Jennifer Moritz, Antonia Schwab, Andreas Reinisch, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 599-599
Open Access | Times Cited: 2
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian H. Brodermann, et al.
Blood Advances (2024) Vol. 8, Iss. 21, pp. 5590-5597
Open Access | Times Cited: 2
Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development
Nicholas J. Short, Richard Dillon
American Journal of Hematology (2024)
Closed Access | Times Cited: 2
Optimal Post-Remission Consolidation Therapy in Patients with AML
Carlos Jiménez Chillón, Richard Dillon, Nigel H. Russell
Acta Haematologica (2023) Vol. 147, Iss. 2, pp. 147-158
Open Access | Times Cited: 6
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia
Håkon Reikvam, Richard Dillon
Expert Review of Hematology (2024) Vol. 17, Iss. 4-5, pp. 103-106
Open Access | Times Cited: 1
FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia
Eric Wenlong Li, Ngoc Yen Kim Tran, Derek McCulloch, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5771-5771
Open Access | Times Cited: 1
Clonal Dynamics and Relapse Risk Revealed by High-Sensitivity FLT3-Internal Tandem Duplication Detection in Acute Myeloid Leukemia
Kwadwo A. Oduro, Theresa Spivey, Erika M. Moore, et al.
Modern Pathology (2024) Vol. 37, Iss. 9, pp. 100534-100534
Open Access | Times Cited: 1
Measurable residual disease in haematological and solid cancers
Roland B. Walter, Robert Peter Gale
Leukemia (2024) Vol. 38, Iss. 8, pp. 1647-1648
Open Access | Times Cited: 1
Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia
Fumihiko Ouchi, Naoki Shingai, Yuho Najima, et al.
International Journal of Hematology (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top